miR-10b、RHOC及相关基因在肝细胞癌中与转移浸润相关的病理学研究
|
摘要
目的分析肝细胞癌中miR-10b、RHOC及相关基因的表达,探讨这些基因参与肝细胞癌恶性生物学行为,及miR-10b可能参与调控RHOC转移浸润的机制。
材料和方法选取2000年1月至2005年12月在我院行手术切除的肝细胞癌病例,共375例,获得随访信息185例。分析本组病例临床病理特征及与预后的关系。留取2007～2008年间手术切除的新鲜肝细胞癌及癌旁肝组织标本19例,western blot检测RHOC蛋白的表达,免疫组化检测cyclin D1、P21WAF1的表达,分析其相关性及与临床病理特征的关系;选取有随访资料的病例80例,免疫组化检测cyclin D1、P21WAF1、p53、ki-67及GPC3在肝细胞癌中的表达,分析各基因表达与临床病理特征的关系及各基因表达之间的相关性;Kaplan-Meier生存分析分析各基因表达的预后意义;COX风险模型分析各临床病理特征及基因表达的预后意义。提取新鲜肝细胞癌及癌旁肝组织中的RNA,实时定量PCR法检测miR-10b和RHOC mRNA基因的表达,分析二者相关性及与临床病理特征的关系。
结果1.本组资料显示肝细胞癌发病年龄19～72岁,平均50.57±10.46岁,发病高峰年龄40～60岁,男女比例为10.7:1;HBsAg(+)87.4%,anti-HCV抗体(+)4.3%;术后3年生存率为52%,5年生存率为38%;肿瘤数目(p=0.000)、肿瘤大小(p=0.025)、组织学结构类型(p=0.000)、核分级(p=0.000)、分化程度(p=0.001)及血管浸润均(p=0.000)与预后明显相关;其中组织学结构类型中细梁状型生存时间与致密梁状型和腺样型无明显区别(p＞0.05)而明显高于粗梁状型、实性型和硬化型(p≤0.009),硬化型生存时间与实性型之间无明显区(p＞0.05)而明显低于其余各型(p≤0.006);核分级1级与2级生存时间无明显区别(p＞0.05),核分级3级与4级生存时间无明显区别(p＞0.05),而核分级3级生存时间明显低于2(p=0.000);小细胞型、巨细胞型和梭形细胞型主要由实性型和粗梁状型组织学结构类型构成,明显不同于透明细胞型(主要由细梁状型和粗梁状型构成)(p≤1.006)。
2.Western blot显示9/19例肝细胞癌中RHOC蛋白高表达,与血管浸润明显相关(p=0.020)。RHOC阳性表达与cyclin D1阳性表达明显正相关(P=0.010);cyclin D1阳性表达与高核分级明显相关(p=0.041);p21~(WAF1)及p53阳性表达均与分化程度(分别为p=0.032,p=0.031)和血管浸润(p=0.036,p=0.011)正相关;ki67阳性表达与分化程度(p=0.004)、核分级(p=0.045)和血管浸润(p=0.001)正相关;GPC3表达与肿瘤数目(p=0.038)和分化程度(p=0.013)正相关。生存分析显示cyclin D1及ki67有明显预后意义。ki67阳性表达与p53(p=0.000)及p21~(WAF1)(p=0.047)阳性表达有明显相关性,其他各基因之间表达无明显关系。
3.COX回归模型分析显示肿瘤大小(p=0.042)、肿瘤数目(p=0.004)及血管浸润(p=0.000)为独立预后因素。
4.与癌旁肝组织相比,miR-10b在肝细胞癌中的平均表达增高(p=0.049),但miR-10b低表达组血管浸润明显高于高表达组(P=0.020);与癌旁肝组织相比,RHOC mRNA在癌组织中的表达增高(P=0.032),同时RHOCmRNA高表达组血管浸润明显高于低表达组(P=0.041)。miR-10b和RHOC mRNA的表达未发现有明显相关性。
结论1.除肿瘤大小、肿瘤数量、分化程度、血管浸润以外,肝细胞癌组织学结构类型和核分级均有明显预后意义。
2.miR-10b、RHOC、cyclin D1、ki67及GPC3均参了与肝细胞癌的生物学进程;RHOC可能参与了细胞周期调控。cyclin D1及ki67有明显预后意义。GPC3可作为肿瘤标记物。miR-10b与RHOC的表达无明显相关性。
3.COX回归模型分析显示肿瘤大小、肿瘤数目及血管浸润为独立预后因素。
Object To evaluate the invasion and metastasis caused by miR-10b,RHOC and related genes in hepatocellular carcionoma(HCC).
Materials and methods The clinical and pathological characteristics of 375 cases of HCC were analysised,which were collected from The general hospital of the People's Liberation Army between 2000 and 2005.Of which 185 case's follow up information had been obtained.And 19 fresh HCC specimens and corresponding pericarcinomatous liver tissues were obtained by surgical resection in The general hospital of the People's Liberation Army between 2007 and 2008. Western blotting was used to investigate the expression of RHOC protein.80 cases with follow up information were examined by immunohistochemically staining to investigate the expression of cyclin D1、P21WAF1、p53、ki-67 and GPC3 genes.The relationship between the genes expression and clinicopathologic characteristics of HCC were evaluated,the clinicopathologic factors and the genes were analyzed by Kaplan-Meier and multivariate COX regression analysis. Of the 19 fresh HCC specimens and corresponding pericarcinomatous liver tissues, Real time quantitate PCR was performed to investigate the expression of miR-10b and RHOC mRNA.
Results 1.These 375 patients had a median age of 50.57±10.46(range,19-72) with 87.4%HBsAg positive and 4.3%anti-HCV antibody positive;The apparent peak incidence age was 40～60 years old,and the ratio of male to female was 10.7:1;The 3 and 5 year postoperational survival rate were 52%and 38%;The tumour numbers(p=0.000),tumor size(p=0.025),histological pattern (p=0.000),nuclear features(p=0.000),differentiation(p=0.001) and vascular invasion(p=0.000) were significantly correlated with prognosis.The postoperational survival time of thin trabeculae pattern,compact pattern and pseudoglandular pattern were significantly longer than that of thick trabeculae, scirrhous pattern,and solid pattern(p＜0.009);the postoperational survival time of 1 and 2 grade based on nuclear features were significantly longer than that of 3 and 4 grades(p=0.000);The small cell variant,osteoclast-like giant cell variant, and spindle cell variant were mainly composed of thick trabeculae pattern and solid pattern,which were significantly different from that of clear cell variant.(p≤0.006).
2.RHOC protein expression was higher in HCC than pericarcinomatous liver tissues in 9/19 cases,and its positive expression was correlated with vien invasion(p=0.020).RHOC expression was positively correlated with cyclin D1 (P=0.023).Increased expression of cyclin D1 was significantly correlated with increasing nuclear grade(p=0.041);High expression of p21~(WAF1) and p53 were significantly correlated with poor tumor differentiation(p=0.032,p=0.031) and vascular invasion(p=0.036,p=0.011);High expression of ki67 was significantly correlated with poor tumor differentiation(p=0.004),increasing nuclear grade(p=0.045) and vascular invasion(p=0.001).Expression of GPC3 was positively correlated with multi-tumour numbers(p=0.038) and poor tumor differentiation(p=0.013).
3.On COX regression analysis,tumour size(p=0.042),tuomr numbers (p=0.004) and vascular invasion(p=0.000) were independent predictors of overall survival.
4.miR-10b and RHOC mRNA expression levels in HCC were higher than that of in pericarcinomatous liver tissues,but lower expression of miR-10b was correlated with vien invasion(p=0.020),contrastly,higher expression of RHOC mRNA was correlated with vien invasion(P=0.041).But the significantly correlation was not found between the expression of miR-10b and RHOC mRNA(p＞0.05).
Conclusion 1.As well as tumor size,tumor numbers,tumor differentiation and vascular invasion of HCC,The histological pattern and nuclear features have prognostic significance.
2.miR-10b,RHOC,cyclin D1,ki67 and GPC3 associate with aggressive of HCC;RHOC may also regulate cell cycle;Cyclin D1 and ki67 have prognostic significance;GPC3 can be a tumour marker in HCC;The expression of miR-10b and RHOC mRNA has no significantly correlation.
3.On COX regression analysis,tumour size,tuomur numbers and vascular invasion were independent predictors of overall survival.
材料和方法选取2000年1月至2005年12月在我院行手术切除的肝细胞癌病例,共375例,获得随访信息185例。分析本组病例临床病理特征及与预后的关系。留取2007～2008年间手术切除的新鲜肝细胞癌及癌旁肝组织标本19例,western blot检测RHOC蛋白的表达,免疫组化检测cyclin D1、P21WAF1的表达,分析其相关性及与临床病理特征的关系;选取有随访资料的病例80例,免疫组化检测cyclin D1、P21WAF1、p53、ki-67及GPC3在肝细胞癌中的表达,分析各基因表达与临床病理特征的关系及各基因表达之间的相关性;Kaplan-Meier生存分析分析各基因表达的预后意义;COX风险模型分析各临床病理特征及基因表达的预后意义。提取新鲜肝细胞癌及癌旁肝组织中的RNA,实时定量PCR法检测miR-10b和RHOC mRNA基因的表达,分析二者相关性及与临床病理特征的关系。
结果1.本组资料显示肝细胞癌发病年龄19～72岁,平均50.57±10.46岁,发病高峰年龄40～60岁,男女比例为10.7:1;HBsAg(+)87.4%,anti-HCV抗体(+)4.3%;术后3年生存率为52%,5年生存率为38%;肿瘤数目(p=0.000)、肿瘤大小(p=0.025)、组织学结构类型(p=0.000)、核分级(p=0.000)、分化程度(p=0.001)及血管浸润均(p=0.000)与预后明显相关;其中组织学结构类型中细梁状型生存时间与致密梁状型和腺样型无明显区别(p＞0.05)而明显高于粗梁状型、实性型和硬化型(p≤0.009),硬化型生存时间与实性型之间无明显区(p＞0.05)而明显低于其余各型(p≤0.006);核分级1级与2级生存时间无明显区别(p＞0.05),核分级3级与4级生存时间无明显区别(p＞0.05),而核分级3级生存时间明显低于2(p=0.000);小细胞型、巨细胞型和梭形细胞型主要由实性型和粗梁状型组织学结构类型构成,明显不同于透明细胞型(主要由细梁状型和粗梁状型构成)(p≤1.006)。
2.Western blot显示9/19例肝细胞癌中RHOC蛋白高表达,与血管浸润明显相关(p=0.020)。RHOC阳性表达与cyclin D1阳性表达明显正相关(P=0.010);cyclin D1阳性表达与高核分级明显相关(p=0.041);p21~(WAF1)及p53阳性表达均与分化程度(分别为p=0.032,p=0.031)和血管浸润(p=0.036,p=0.011)正相关;ki67阳性表达与分化程度(p=0.004)、核分级(p=0.045)和血管浸润(p=0.001)正相关;GPC3表达与肿瘤数目(p=0.038)和分化程度(p=0.013)正相关。生存分析显示cyclin D1及ki67有明显预后意义。ki67阳性表达与p53(p=0.000)及p21~(WAF1)(p=0.047)阳性表达有明显相关性,其他各基因之间表达无明显关系。
3.COX回归模型分析显示肿瘤大小(p=0.042)、肿瘤数目(p=0.004)及血管浸润(p=0.000)为独立预后因素。
4.与癌旁肝组织相比,miR-10b在肝细胞癌中的平均表达增高(p=0.049),但miR-10b低表达组血管浸润明显高于高表达组(P=0.020);与癌旁肝组织相比,RHOC mRNA在癌组织中的表达增高(P=0.032),同时RHOCmRNA高表达组血管浸润明显高于低表达组(P=0.041)。miR-10b和RHOC mRNA的表达未发现有明显相关性。
结论1.除肿瘤大小、肿瘤数量、分化程度、血管浸润以外,肝细胞癌组织学结构类型和核分级均有明显预后意义。
2.miR-10b、RHOC、cyclin D1、ki67及GPC3均参了与肝细胞癌的生物学进程;RHOC可能参与了细胞周期调控。cyclin D1及ki67有明显预后意义。GPC3可作为肿瘤标记物。miR-10b与RHOC的表达无明显相关性。
3.COX回归模型分析显示肿瘤大小、肿瘤数目及血管浸润为独立预后因素。
Object To evaluate the invasion and metastasis caused by miR-10b,RHOC and related genes in hepatocellular carcionoma(HCC).
Materials and methods The clinical and pathological characteristics of 375 cases of HCC were analysised,which were collected from The general hospital of the People's Liberation Army between 2000 and 2005.Of which 185 case's follow up information had been obtained.And 19 fresh HCC specimens and corresponding pericarcinomatous liver tissues were obtained by surgical resection in The general hospital of the People's Liberation Army between 2007 and 2008. Western blotting was used to investigate the expression of RHOC protein.80 cases with follow up information were examined by immunohistochemically staining to investigate the expression of cyclin D1、P21WAF1、p53、ki-67 and GPC3 genes.The relationship between the genes expression and clinicopathologic characteristics of HCC were evaluated,the clinicopathologic factors and the genes were analyzed by Kaplan-Meier and multivariate COX regression analysis. Of the 19 fresh HCC specimens and corresponding pericarcinomatous liver tissues, Real time quantitate PCR was performed to investigate the expression of miR-10b and RHOC mRNA.
Results 1.These 375 patients had a median age of 50.57±10.46(range,19-72) with 87.4%HBsAg positive and 4.3%anti-HCV antibody positive;The apparent peak incidence age was 40～60 years old,and the ratio of male to female was 10.7:1;The 3 and 5 year postoperational survival rate were 52%and 38%;The tumour numbers(p=0.000),tumor size(p=0.025),histological pattern (p=0.000),nuclear features(p=0.000),differentiation(p=0.001) and vascular invasion(p=0.000) were significantly correlated with prognosis.The postoperational survival time of thin trabeculae pattern,compact pattern and pseudoglandular pattern were significantly longer than that of thick trabeculae, scirrhous pattern,and solid pattern(p＜0.009);the postoperational survival time of 1 and 2 grade based on nuclear features were significantly longer than that of 3 and 4 grades(p=0.000);The small cell variant,osteoclast-like giant cell variant, and spindle cell variant were mainly composed of thick trabeculae pattern and solid pattern,which were significantly different from that of clear cell variant.(p≤0.006).
2.RHOC protein expression was higher in HCC than pericarcinomatous liver tissues in 9/19 cases,and its positive expression was correlated with vien invasion(p=0.020).RHOC expression was positively correlated with cyclin D1 (P=0.023).Increased expression of cyclin D1 was significantly correlated with increasing nuclear grade(p=0.041);High expression of p21~(WAF1) and p53 were significantly correlated with poor tumor differentiation(p=0.032,p=0.031) and vascular invasion(p=0.036,p=0.011);High expression of ki67 was significantly correlated with poor tumor differentiation(p=0.004),increasing nuclear grade(p=0.045) and vascular invasion(p=0.001).Expression of GPC3 was positively correlated with multi-tumour numbers(p=0.038) and poor tumor differentiation(p=0.013).
3.On COX regression analysis,tumour size(p=0.042),tuomr numbers (p=0.004) and vascular invasion(p=0.000) were independent predictors of overall survival.
4.miR-10b and RHOC mRNA expression levels in HCC were higher than that of in pericarcinomatous liver tissues,but lower expression of miR-10b was correlated with vien invasion(p=0.020),contrastly,higher expression of RHOC mRNA was correlated with vien invasion(P=0.041).But the significantly correlation was not found between the expression of miR-10b and RHOC mRNA(p＞0.05).
Conclusion 1.As well as tumor size,tumor numbers,tumor differentiation and vascular invasion of HCC,The histological pattern and nuclear features have prognostic significance.
2.miR-10b,RHOC,cyclin D1,ki67 and GPC3 associate with aggressive of HCC;RHOC may also regulate cell cycle;Cyclin D1 and ki67 have prognostic significance;GPC3 can be a tumour marker in HCC;The expression of miR-10b and RHOC mRNA has no significantly correlation.
3.On COX regression analysis,tumour size,tuomur numbers and vascular invasion were independent predictors of overall survival.
引文
1.World Health Organization.Mortality database.Available from:URL:http://www.who.int/whosis/en
2.Jong-wook L.Global health improvement and WHO shaping the future.Lancet.2003,362:2083-2088.
3.Sherman M.Hepatocellular carcinoma:epidemiology,risk factors,and screening.Semin Liver Dis.2005,25:143-154.
4.Bosch FX,Ribes J,Diaz M,et al.Primary liver cancer:worldwide incidence and trends.Gastroenterology.2004,127:S5-S1.
5.Clark EA,Golob TR,Lander ES,et al.Genomic analysis of metastasis reveals an essential role for Rhoc[J],Nature.2000,406:532-535.
6.Machesky LM,Hall A.Rho:a connection between membrane recep2 for signalling and the cytoskeleton.Trends Cell B iol,1996,6(8):3042 310.
7.Oxford G,Theodorescu D.Ras superfamily monomeric G proteins in carcinoma cell motility.Cancer Letters,2003,189(2):117-128.
8.Celina GK,Kent AG,Michael SS,et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.Breast Cancer Research and Treatment.2005,93:101-110.
9.Kondo T,Sentani K,Oue N,et al.Exp ressi on of RhoC is ass ociated with metastasis of gastric carcinoma.Pathobiology.2004,71(1):19-25.
10.TakamuraM,SakamotoM,Genda T,et al.I nhibiti on of intrahepatic metastasis of human hepatocellular carcinoma by Rho2 associated protein kinase inhibitor Y2 27632.Hepatology.2001,33 (3):2.
11.Tomari Y,Zamore PD.MicroRNA biogenesiss:drosha can't cut it without a partner.Curr Biol.2005,15(2):R61-64.
12.Lewis BP,Burge CB,Bartel DP.Conserved seed pairing,often flanked by adenosines,indicates that thousands of human genes are microRNA targets.Cell.2005.120:15-20.
13.Zhang BH,Wang QL,Pan XP.MicroRNAs and their regulatory roles in animals and plants.J Cell Physiol.2007,210:279-289.
14.Calin G.A,Sevignani C,Dan Dumitru C,et al.Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.Proc.Natl.Acad.Sci.U.S.A.2004,101:2999-3004.
15.Voorhoeve PM,le Sage C,Schrier M,et al.Agenetic serene implicates miRNA-372 and miRNA-373 as oncogenes in testicular germcell tumors.Cell.2006,124(6):1169-1181.
16.Johnson SM,Grosshans H,Shingara J,et al.RAS is regulated by the let-7 microRNA family.Cell.2005,120(5):635-647.
17.Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.Cancer Res.2004,64(11):3753-3756.
18.Calin GA,Dumitru CD,Shimizu M,et al.Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc Natl Acad Sci USA.2002,99:15524-15529
19.Michael MZ,AM OC,Van Hoist Pellekaan NG,et al.Reduced accumulation of specific microRNAs in colorectal neoplasia.Mol Cancer Res.2003,1(12):882-891.
20.Ciafre SA,Galardi S,Mangiola A,et al.Extensive modulation of a set of microRNAs in primary glioblastoma.Biochem Biophys Rse Commun.2005,334(4):1351-1358.
21.Iorio MV,Ferracin M,Liu CG,et al.MicroRNA gene expression deregulation in human breast cancer.Cancer Res.2005,65(16):7065-7070.
22.Yanaihara N,Caplen N,Bowan E,et al.Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.Cancer Cell.2006,9(3):189-198.
23.Ma L,Teruya-Feldstein J,Weinberg RA.Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature.2007,449:682-688.
1.World Health Organization.Mortality database.Available from:URL:http://www.who.int/whosis/en
2.Jong-wook L.Global health improvement and WHO shaping the future.Lancet.2003,362:2083-2088.
3.Sherman M.Hepatocellular carcinoma:epidemiology,risk factors,and screening.Semin □ Liver □ Dis.2005,25:143-154.
4.Bruix J,Llovet,J.M.Prognostic prediction and treatment strategy in hepatocellular carcinoma.Hepatology.2003,35:519-524.
5.Tang ZY,Yu YQ,Zhou XD,et al.Progress and prospects in hepatocellular carcinoma surgery.Ann Chir.1998,52:558-563.
6.陈杰.肝脏、胆道及胰腺疾病.见:陈杰,李甘地,主编.病理学,第一版,北京:人民卫生出版社,2005,294.
7.Zachary D.G,LuigiM.T,Tumours and tumour-like lesions of the liver.In: Alastair D.B,Bernard C.P,Linda D.F.eds.Macsween's pathology of the liver.5 ed.Philadephia:Elsevier.2007,777-785.
8.S.Hirohas,K.G.Ishak,M.Kojiro,et al.Hepatocellular carcinoma.In:Stanley R.Hamilton,Lauri A.Aaltonen.Eds.Pathology and Genetics of Tumours of the Digestive System.Lyon:IARCPress.2003,164-166.
9.Ishak KG,Goodman ZD,Stocker JT.Tumors of the liver an intrahepatic bile ducts.Atlas of tumor pathology,3~(rd) Series,Fascicle 31.Washington:Armed Forces Institute of Pathology.2001.
10.Scheuer PJ.Classification of chronic viral hepatitis.A need for reassessment.J Hepatol.1991,13:372-374.
11.Bosch FX,Ribes J,Diaz M,et al.Primary liver cancer:Worldwide incidence and trends.Gastroenterology.2004,127:S5-S16.
12.Nagasue N,Ito A,Yukaya H,et al.Androgen receptors in hepatocellular carcinoma and surrounding parenchyma.Gastroenterology.1985,89:643-647.
13.Montalto G,Cervello M,Giannitrapani L,et al.Epidemiology,risk factors,and natural history of hepatocellular carcinoma.Ann N Y Acad Sci.2002,963:13-20.
14.Michielsen PP,Francque SM,van Dongen JL.Viral hepatitis and hepatocellular carcinoma.World J Surg Oncol.2005,3:27.
15.Edmondson HA,Steiner PE.Primary carcinoma of the liver:A study of 100 cases among 48900 necropsies.Cancer.1954,7:462-503.
16.Lauwers GY,Terris B,Balis UJ,et al.Prognostic histologic indicators of curatively resected hepatocellular carcinoma:a multi-institutional analysis of 425 patients with definition of a histologic prognostic index.Am J Surg Pathol.2002,26:25-34.
17.Nzeako UC,Goodman ZD,Ishak KG.Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma.Cancer.1995,76:579-588.
18.Llovet JM,Bustamante J,Castells A,et al.Natural history of untreated nonsurgical hepatocellular carcinoma:rationale for the design and evaluation of therapeutic trials.Hepatology.1999,29(1):62-67.
19.El-Assal ON,Yamanoi A,Soda Y,et al.Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma.Surgery.1997,122:571-577.
20.Villa E,Moles A,Ferretti I,et al.Natural history of inoperable hepatocellular carcinoma:estrogen receptors' status in the tumor is the strongest prognostic factor for survival.Hepatology.2000,32:233-238.
1.Sahai E,Marshall CJ.RhoGTPases and cancer.Nat Rev Cancer.2002,2:133-142.
2.Celina GK,Kent AG,Michael SS,et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.Breast Cancer Research and Treatment.2005,93:101-110.
3.Na L,Guoyun Zh,Feng B,et al.RhoC is essential for the metastasis of gastric cancer.J Mol Med.2007,85:1149-1156.
4.Wei W,Lian-Yue Y,Zhi-Li Y,et al.Expression and significance of RhoC gene in hepatocellular carcinoma.World J Gastroenterol.2003,9(9):1950-1953.
5.Joo M,Kang YK,Kim MR,et al.CyclinD 1 overexpression in hepatocellular carcinoma.Liver.2001,21:89-95.
6.Gartd AL,Radhakfishnan SK.Lost in transeription:p 21 repression mechanisms,and consequences.Cancer Res.2005,65(10):3980-3985.
7.Katiyar S,Dash BC,Thakur V,et al.P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.Cancer.2000,88:1565-1573.
8.KL Watts,E Cottrell,PR Hoban,et al.RhoA signaling modulates cyclin D1expression in human lung fibroblasts;implications for idiopathic pulmonary fibrosis.Respiratory Research.2006,7:88.
9.Welsh CF:Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.Breast Cancer Res Treat.2004,84(1):33-42.
10.Filmus J,Selleck SB.Glypicans:proteoglycans with a surprise.J Clin Invest.2001,108:497- 501.
11.Sung YK,Hwang SY,Park MK,et al.Glypican-3 is overexpressed in human hepatocellular carcinoma.Cancer Sci.2003,94:259-262.
12.Nakatsura T,Kageshita T,Ito S,et al.Identification of glypican-3 as a novel tumor marker for melanoma.Clin Cancer Res.2004,10:6612-6621.
13.Zynger DL,Dimov ND,Luan C,et al.Glypican 3:a novel marker in testicular germ cell tumors.Am J Surg Pathol.2006,30:1570-1575.
14.Clark EA,Golub TR,Lander ES,et al.Genomic analysis of metastasis reveals an essential role for RhoC [J].Nature.2000,406 (6795):532-535.
15.Kondo T,Sentani K,Oue N,et al.Exp ressi on of RhoC is ass ociated with metastasis of gastric carcinoma.Pathobiology.2004,71 (1):19-25.
16.Bohmer RM,Scharf E,Assoian RK.Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates the anchorage-dependent expression of cyclinD1.Mol.Biol.Cell.1996,7:101-111.
17.Nobes CD,Hall A.Rho,Rac,and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers,lamellipodia,and filipodia.Cell.1995,81,53-62.
18.Catherine F,Welsh,Kristin R,et al.Timing of cyclindl espression within G1 phase is controlled by RHO.Natrre cell biology.2001,3:950-957.
19.Quelle DE,Ashmun RA,Shurtleff SA,et al.Overexpression of mouse D-type cyclins accelerates Gl phase in rodent fibroblasts.Genes Dev.1993,7:1559-1571.
20.Bodrug SE,Warner BJ,Bath ML,et al.Cyclin Dl transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene.EMBO J.1994,13:2124-2130.
21.Gladden AB,Woolery R,Aggarwal P,et al.Expression of constitutively nuclear cyclin Dl in murine lymphocytes induces B-cell lymphoma.Oncogene.2006,25:998-1007.
22.Azechi H,Nishida N,Fukuda Y,et al.Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas.Oncology.2001,60:346-354.
23.Choi YL,Park SH,Jang JJ,et al.Expression of the G1-S modulators in hepatitis B virus-related hepatocel lular carcinoma and dysplastic nodule:association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma J Korean Med Sci.2001,16:424-432.
24.Somasundaram K,Zhang H,Zeng YX,et al.Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.Nature.1997,389:187-190.
25.Caffo O,Doglioni C,Veronese S,et al.Prognostic value of p21(WAF1) and p53 expression in breast carcinoma:an immunohistochemical study in 261patients with long-term follow-up.Clin Cancer Res.1996,2:1591-1599.
26.Thor AD,Liu S,Moore DH,et al.p(21WAF1/CIP1) expression in breast cancers:associations with p53 and outcome.Breast Cancer Res Treat.2000,61:33-43.
27.Nemes JA,Nemes Z,Mrton IJ.p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma.J Oral Pathol Med.2005,34(5):274-279.
28.Mitomi H,Ohkura Y,Fukui N.P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.Eur J Gastroenterol Hepatol.2007.19(10):883-889.
29.Domagala W,Welcker M,Chosia M,et al.p21/WAF1/Cip1 expression in invasive ductal breast carcinoma:relationship to p53,proliferation rate,and survival at 5 years.Virchows Arch.2001,439:132-140.
30.Primdahl H,von der Maase H,Sorensen FB,et al.Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer.J Cancer Res Clin Oncol 2002;128:295-301.
31.Gohring UJ,Bersch A,Becker M,et al.p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.J Clin Pathol.2001,54:866-870.
32.Lipponen P,Aaltomaa S,Eskelinen M,et al.Expression of p21(Wafl/Cip1) protein in transitional cell bladder tumours and its prognostic value.Eur Urol.1998,34:237-243.
33.Kao JT,Chuah SK,Huang CC.P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.Liver Int.2007,27(6):772-781.
34.Park YN,Chae KJ.Kwon KW.p53 and p21WAF1/CIP1 in hepatitis B virus related hepatocarcinogenesis.Hepatogastroenterologv.2003,50(53):1292-1296.
35.McClelland RA,Gee JM,O'Sullivan L,et al.p21(WAF1) expression and endocrine response in breast cancer.J Pathol.1999,188:126-130.
36.Susumu Kobayashi,Kazuyuki Matsushita,Kenichi Saigo,et al.p21WAF1/CIP1 Messenger RNA Expression in Hepatitis B,C Virus-Infected Human Hepatocellular Carcinoma Tissues.CANCER.2001,91 (11):2096-2103.
37.Qin LF,Ng IP.Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma:clinicopathologic correlation and survival analysis.Hum Pathol.2001,32(8):778-784.
38.Park YN,Chae KL Kwon KW,et al.p53 and p21WAF1/CIP1 in hepatitis B virus related hepatocarcinogenesis.Hepatogastroenterology.2003,50(53):1292-1296.
39.Bouchard MJ,Wang L,Schneider RJ.Activation of focal adhesion kirtase by hepatitis B virus HBx protein:multiple functions in viral replication.J Virol.2006,80:4406-4414.
40.Fujimoto Y,Hampton LL,Wirth PJ,et al.Alterations of Tumor Suppressor Genes and Allelic Losses in Human Heoatocellular Carcinomas in China.Cancer Res.1994,54(1):281-285.
41.White GR,Kelsey AM,Varley JM,et al.Somatic glypican-3(GPC3) mutations in Wilm' tumour.Br J Cancer.2003,86:1920-1922.
42.Capurro M,Wanless IR,Sherman M,et al.Gylpican-3:a novel serum and histochemical marker for hepatocellular carcinoma.Gastroenterology.2003,125:89-97.
43.Yamauchi N,Watanabe A.Hishinuma M,et al.The glypican-3 oncofetal protein is a promising siagnostic marker for hepatocellular carcinoma.Mod Pathol.2005,18:1591-1598.
44.Zhu ZW,Friess H,Wang L,et al.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.Gut.2001,48:558-564
45.Coggin,J.H.Jr.The implications of embryonic gene expression in neoplasia.CRC Crit.Rev.Onco J Hemat.1992,5:37-55.
46.M J Pellikainen,T T Pekola,K M Ropponen,et al.p21WAF1 expression in invasive breast cancer and it association with p53,AP-2,cell proliferation,and prognosis.J Clin Pathol.2003,56:214-220.
1.Tung P,Poon R,Fan ST,et al.Risk factors,prevention,and management of postoperative recurrence after resection of hepatocellular carcinoma.Ann Surg.2000,232:10-24.
2.Clark EA,Golub TR,Lander ES,et al.Genomic analysis of metastasis reveals an essential role for RhoC.Nature.2000,406 (6795):5322 535.
3.Celina GK,Kent AG,Michael SS,et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.Breast Cancer Research and Treatment.2005,93:101-110.
4.Na L,Guoyun Z,Feng B,et al.RhoC is essential for the metastasis of gastric cancer,J Mol Med.2007,85:1149-1156.
5.Wei W,Lian-Yue Y,Zhi-Li Y,et al.Expression and significance of RhoC gene in hepatocellular carcinoma,World J Gastroenterol.2003,9(9):1950-1953
6.Lewis BP,Burge CB,Bartel DP.Conserved seed pairing,often flanked by adenosines,indicates that thousands of human genes are microRNA targets.Cell.2005,120:15-20.
7.Xie XH,Lu J,Kulbokas EJ,et al.Systematic discovery of regulatory motifs in human promoters and 3'UTRs by comparison of several mammals.Nature.2005,434:338-345.
8.Calin GA,Croce C M.MicroRNA signatures in human cancers.Nature Rev.Cancer.2006,6:857-866.
9.Ma L,Teruya-Feldstein J,Weinberg RA.Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature.2007,449:682-688.
10.Fu HJ,Zhu J,Yang M,et al.A novel method to monitor the expression of microRNAs.Mol Biotechnol.2006,32:197-204.
11.Lee RC,Feinbaum RL,Ambros V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.Cell.1993,75:843-854.
12.Reinhart BJ,Slack FJ,Basson M,et al.The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans.Nature.2000,403:901-906.
13.Pasquinelli AE,Reinhart BJ,Slack F,et al.Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA.Nature.2000,408:86-89.
14.Denli AM,Tops BBJ,Plasterk RHA,Ketting RF,Harmon et al.Processing of primary microRNAs by the microprocessor complex.Nature.2004,432:231.
15.Forstemann K,Tomari Y,Du TT,et al.Normal microRNA maturation and germ-line stem cell maintenance requires loqua-cious,a double-stranded RNA-binding domain protein.Plos Biol.2005,3:1187-201.
16.Zhang BH,Pan XP,Cobb GP,et al.microRNAs as oncogenes and tumor suppressors.Dev Biol.2007,302:1-12.
17.Zhang BH,Wang QL,Pan XP.MicroRNAs and their regulatory roles in animals and plants.J Cell Physiol.2007,210:279-289.
18.Bentwich I,Aviniel A,Karov Y,et al.Identification of hundreds of conserved and nonconserved human microRNAs.Nature Genet.2005,37(7):766-770.
19.Xie XH,Lu J,Kulbokas EJ,et al.Systematic discovery of regulatory motifs in human promotersand 3'UTRs by comparison of several mammals.Nature.2005,434:338-345.
20.Zhang BH,Pan XP,Anderson TA.MicroRNA:a new player in stem cells.J Cell Physiol.2006,209:266-269.
21.Volinia S,Calin GA,Liu CG,et al.A microRNA expression signature of human solid tumors defines cancer gene targets.Proc.Natl.Acad.Sci.U.S.A.2006,103:2257-2261.
22.Calin GA,Dumitru CD,Shimizu M,et al.Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc Natl Acad Sci USA.2002,99:15524-15529.
23.Esquela-Kerscher A,Slack FJ.Oncomirs-microRNAs with a role in cancer.Nature Rev.Cancer.2006,6:259-269.
24.Johnson SM.et al.RAS is regulated by the let-7 microRNA family.Cell.2005,120:635-647.
25.Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.Cancer Res.2004,64(11):3753-3756.
26.Iorio MV,Ferracin M,Liu CG,et al.MicroRNA gene expression deregulation in human breast cancer.Cancer Res.2005,65(16):7065-7070.
27.Volinia S,Calin GA,Lin CG,et al.A microRNA expression signature of human solid tumors define cancer gene targets.Proc Natl Acad Sci USA.2006,103(7):2257-2261.
28.He L,Thomson JM,Hemann MT,et al.A microRNA polycistron as a potential human oncogene.Nature.2005,435(7043):828-833.
29.Garzon R,Garofalo M,Martelli MP,et al.Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.PNAS.2008,105:3945-3950.
30.Falini B,Nicoletti I,Martelli FM,et al.Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc_ AML):Biological and clinical features.Blood.2007,109:874-885.
31.Ladeiro Y,Couchy G,Balabaud C,et al.MicroRNA Profiling in Hepatocellular Tumors Is Associated with Clinical Features and Oncogene/Tumor Suppressor Gene Mutations.Hepatology.2008,47:1955-1963.
32.Oxford G,Theodorescu D.Ras superfamily monomeric G p roteins in carcinoma cell motility.Cancer Letters.2003,189 (2):117-128.
1.Motola-Kuba D,Zamora-Valdes D,Uribe M,et al.Hepatocellular carcinoma.An overview.Ann Hepatol,2006,5:16-24.
2.Gorog D,Regoly-Merei J,Paku S,et al.Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.World-J-Gastroenterol,2005,11(32):5015-5018.
3.Ramos Vara JA,Miller MA,Johnson GC.Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.Vet-Pathol,2001,38(6):636-643.
4.Lugli A,Tornillo L,Mirlacher M,et al.Hepatocyte paraffin 1 expression in human normal and neoplastic tissues:tissue microarray analysis on 3,940 tissue samples[J].Am-J-Clin-Pathol,2004,122(5):721-727.
5.Zhu ZW,Friess H,Wang L,et al.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders[J].Gut.,2001,48(4):558-564.
6.Yamauchi N,Watanabe A,Hishinuma M,et al.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma[J].Mod-Pathol,2005,18(12):1591-1598.
7.Wang XY,Degos F,Dubois S,et al.Glypican-3 expression in hepatocellular tumors:diagnostic value for preneoplastic lesions and hepatocellular carcinomas[J].Hum-Pathol,2006,37(11):1435-1441.
8.Libbrecht L,Severi T,Cassiman D,et al.Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis,dysplastic nodules,and focal nodular hyperplasia-like nodules[J].Am-J-Surg-Pathol,2006,30(11):1405-1411.
9.De Boer WB,Segal A,Frost FA,et al.Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies [J].Cancer,2000,90(5):273-278.
10.韩圣华,黄建富.新生血管生成与肝细胞癌侵袭、转移和预后的关系[J].中华肝胆外科杂志,2001,7(1):27-30.
11.Borscheri N,Roessner A,Rocken C.Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas[J].Am-J-Surg-Pathol,2001,25(10):1297-1303.
12.Xiao SY,Wang HL,Hart J,et al.cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma[J].Am-J-Pathol,2001,159(4):1415-1421.
13.Zimmerman RL,Logani S,Baloch Z.Evaluation of the CD34 and CD10immunostains using a two-color staining protocol in liver fine-needle aspiration biopsies[J].Diagn-Cytopathol,2005,32(2):88-91.
14.Stroescu C,Herlea V,Dragnea A,et al.The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas[J].J-Gastrointestin-Liver-Dis,2006,15(1):9-14.
15.Park YN,Kojiro M,Di-Tommaso L,et al.Ductular reaction is helpful in defining early stromal invasion,small hepatocellular carcinomas,and dysplastic nodules[J].Cancer,2007,109(5):915-923.
16.Athanassiadou P,Psyhoyiou H,Grapsa D,et al.Cytokeratin 8 and 18expression in imprint smears of chronic viral hepatitis,autoimmune hepatitis and hepatocellular carcinoma[J].A preliminary study.Acta-Cytol,2007,51(1):61-65.
17.Lemmer ER,de la Motte Hall P,Omori N,et al.Histopathology and gene expression changes in rat liver during feeding of fumonisin B_1,a carcinogenic mycotoxin produced by Fusarium moniliforme[J].Carcinogenesis,1999,20(5):817-824.
18.Chan KL,Guan XY,Ng IO.High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma[J].Hum-Pathol,2004,35(11):1324-1331.
19.朱斌,姚晓平,杨甲梅,等.原发性肝细胞癌中细胞周期G1期相关基因Cyclin D1的表达及其临床病理学意义[J].肝胆外科杂志,1999,7(3):214-216.
20.Wong CM,Fan ST,Ng IO.beta-Catenin mutation and overexpression in hepatocellular carcinoma:clinicopathologic and prognostic significance[J].Cancer,2001,92:136-145.
21.Zeng G,Apte U,Cieply B,et al.siRNA-Mediated beta-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival[J].Neoplasia,2007,9(11):951-959.
22.Suzuki K,Hayashi N,Yamada Y,et al.Expression of the c-met protooncogene in human hepatocellular carcinoma[J].Hepatology,1994,20(5):1231-1236.
23.Salvi A,Arici B,Portolani N,et al.In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells[J].Int J Oncol,2007,31(2):451-460.
24.Wang XW,Forrester K,Yeh H,et al.Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding,transcriptional activity,and association with transcription factor ERCC3[J].Proc Natl Acad Sci,1994,91:2230-2234.
25.Oda T,Tsuda H,Sakamoto M,et al.Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression[J].Cancer Lett,1994,83:197-200.
26.Bouchard M J,Wang L,Schneider RJ.Activation of focal adhesion kirtase by hepatitis B virus HBx protein:multiple functions in viral replication[J].J Virol,2006,80:4406-4414.
27.Fujimoto Y,Hampton LL,Wirth PJ,et al.Alterations of Tumor Suppressor Genes and Allelic Losses in Human Heoatocellular Carcinomas in China[J].Cancer Res 1994;54(1):281- 285.
28.Moghaddam S J,Haghighi EN,Samiee S,et al.Immunohistochemical analysis of p53,cyclinD1,RB1,c-fos and N-ras gene expression in hepatocellular carcinoma in Iran.[J].World-J-Gastroenterol,2007,13(4):588-593.
29.Hu TH,Wang CC,Huang CC,et al.Down-regulation of tumor suppressor gene PTEN,overexpression of p53,plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection[J].Oncol Rep,2007,18(6):1417-1426.
30.许荣华,易继林.FHIT基因蛋白的表达与肝癌的临床关系[J].临床外科杂志,2004,12(7):412-414.
31.Kannangai R,Sahin F,Adegbola O,et al.FHIT mRNA and protein expression in hepatocellular carcinoma[J].Mod-Pathol,2004,17(6):653-659.
32.Endo K,Ueda T,Ueyama J,et al.Immunoreactive E-cadherin,alpha-catenin,beta-catenin,and gamma-catenin proteins in hepatocellular c arcinoma:relationships with tumor grade,clinicopathologic parameters,and pati ents'survival[J].Hum Pathol,2000,31:558-565.
33.殷茜,陈孝平.细胞黏附分子CD44v6在肝癌组织中的表达及意义[J].世界华人消化杂志,2005,13(11):1295-1298.
34.Musso O,Th(?)ret N,Campion JP,et al.In situ detection of matrix metalloproteinase-2(MMP2) and the metalloproteinase inhibitor TIMP2transcripts in human primary hepatocellular carcinoma and in liver metastasis[J].J Hepatol,1997,26(3):593-605.
35.Murakami Y,Yasuda T,Saigo K,et al.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J].Oncogene,2006,25:2537-2545.
36.Meng F,Henson R,Wehbe-Janek H,et al.MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer[J].Gastroenterology,2007,133(2):647-58.Epub 2007 May 21.
1.Calin GA,Sevignani C,Dan Dumitru C,et al..Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J].Proc.Natl.Acad.Sci.U.S.A.2004,101:2999-3004.
2.Zhang BH,Pan XP,Cox SB,et al.Evidence that miRNAs are different from other RNAs[J].Cell.Mol.Life Sci.2006,63:246-254.
3.Iin H,Gregory J H.MicroRNAs:small RNAs with a big role in gene regulation[J].Nature Rev Genet,2004,5:522.
4.Xu PZ,Guo M,Hay BA.MicroRNAs and the regulationof cell death[J].Trends Genet,2004,20:617.
5.Volinia S,Calin GA,Liu CG,et al.A microRNA expression signature of human solid tumors defines cancer gene targets[J].Proc.Natl.Acad.Sci.U.S.A, 2006,103:2257-2261.
6.Zhang BH,Pan XP,Cobb GP,et al.Plant microRNA:a small regulatory molecule with big impact.Dev[J].Biol,2006,289:3-16.
7.Griffiths-Jones S,Grocock RJ,van Dongen S,et al.miRBase:microRNA sequences,targets and gene nomenclature [J].Nucleic Acids Res,2006,34:D140-D144.
8.Lee Y,Kim M,Han J,et al.MicroRNA genes are transcribed by RNA polymerase Ⅱ [J].EMBO J,2004,23(20):4051-4060.
9.Lee Y,Ann C,Han J,et al.The nuclear RNaselll Drosha initiates microRNA processing[J].Nature,2003,425:415-419.
10.Denli AM,Tops BB,Plasterk RH,et al.Processing of primary microRNAs by the microprocessor complex[J].Nature,2004,432:231-235.
11.Zeng Y,Cullen BR.Structural requirements for pre-microRNA binding and nuclear export by Exportin 5[J].Nucleic Acids Research,2004,32(16):4776-4785.
12.Hutvagner G,Zamore PD.A microRNA in a multiple-turnover RNAi enzyme complex[J].Science,2002,297:2056-2060.
13.Chen F,Yin QW.MiRNAs regulate the gene expression.Chinese Science Bulletin[J],2005,50(13):1289-1299.
14.Hutvagner G,Simard MJ,Mello CC,et al.Sequencespecific inhibition of small RNA function[J].PLOS Biol.2004,2:465-475.
15.Krutzfeldt J,Rajewsky N,Braich R,et al.Silencing of microRNAs in vivo with 'antagomirs' [J].Nature,2005,438:685-689.
16.Lewis BP,Burge CB,Bartel DP.Conserved seed pairing,often flanked by adenosines,indicates that thousands of human genes are microRNA targets[J].Cell,2005,120:15-20.
17.Lee RC,Feinbaum RL,Ambros V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J].Cell,1993,75:843-854.
18.Hayashita Y,Osada H,Tatematsu Y,et al.A polycistronic microRNA cluster,miR-17-92,is overexpressed in human lung cancers and enhances cell proliferation[J].Cancer Res,2005,65:9628-9632.
19.Bandres E,Cubedo E,Agirre X,et al.Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues[J].Molecular Cancer,2006,5:29.
20.Thomson JM,Parker J,Perou CM,et al.A custom microarray platform for analysis of microRNA gene expression[J].Nature Methods,2004,1:47-53.
21.Liang RQ,Li W,Li Y,et al.An oligonucleotide microarray for microRNA expression analysis based on labeling RNAwith quantum dot and nanogold probe[J].Nucleic Acids Res,2005,33:e17.
22.Lu J,Getz G,Miska EA,et al.MicroRNA expression profiles classify human cancers[J].Nature,2005,435:834-838.
23.Lewis BP,Shih IH,Jones-Rhoades,et al.Prediction of mammalian microRNA targets[J].Cell,2003,115:787-798.
24.Hammond SM.MicroRNAs as oncogenes[J].Curr.Opin.Genet.Dev.2006,16:4-9.
25.Voorhoeve PM,le Sage C,Schrier M,et al.A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors[J].Cell,2006,124:1169-1181.
26.Reinhart BJ,Slack FJ,Basson M,et al.The 21-nucleotide lct-7 RNA regulates developmental timing in Caenorhabditis elegans[J].Nature,2000,403(6672):901-906.
27.Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival[J].Cancer Res,2004,64:3753-3756.
28.Johnson SM,Grosshans H,Shingara J,et al.RAS is regulated by the let-7 microRNA family[J].Cell,2005,120:635-647.
29.Calin GA,Dumitru CD,Shimizu M,et al.Frequent de2 letions and down2regulation of micro2RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia[J].Proc Natl Acad Sci U S A,2002,99 (24):15524-15529.
30.Calin GA,Liu CG,Sevignani C,et al.MicroRNA profiling reveals distinct signatures in B cell chroniclymphocytic leukemias[J].Proc.Natl.Acad.Sci.U.S.A,2004,101:11755-11760.
31.Cimmino A,Calin GA,Fabbri M,et al.miR-15 and miR-16 induce apoptosis by targeting BCL2[J].Proc.Natl.Acad.Sci.U.S.A.,2005,102;13944-13949.
31.He L,Thomson JM,Hemann MT,et al.A microRNA palycistron as a potential human oncogene[J].Nature,2005,435:828-833.
32.Tam,W.Identification and characterization of human BIC,a gene on chromosome 21 that encodes a noncoding RNA[J].Gene,2001,274:157-167.
33.Eis PS,Tam W,Sun LP,et al.Accumulation of miR-155 and BIC RNA in human Bcell lymphomas[J].Proc.Natl.Acad.Sci.U.S.A,2005,102:3627-3632.
34.Murakami Y,Yasuda T,Saigo K,et al.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J].Oncogene,2006,25:2537-2545.
35.Yingqiu Guo,Yongxin Chen,Hirotaka Ito,et al.Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma[J].Gene,2006,384:51-61.
36.Yang J,Zhou F,Xu T,et al.Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas [J].Mutat Res,2008,628(1-2):205-209.Epub 2007 Aug 21.
37.Meng F,Henson R,Wehbe-Janek H,et al.MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer[J].Gastroenterology,2007,133(2):647-58.Epub 2007 May 21.
38.Iorio MV,Ferracin M,Liu CG,et al.MicroRNA gene expression deregulation in human breast cancer[J].Cancer Res,2005,65:7065-7070.
39.Michael MZ,O'Connor SM.,Pellekaan NGV,et al.Reduced accumulation of specific microRNAs in colorectal neoplasia[J].Mol.Cancer Res,2003,1:882-891.
40.Ciafre SA,Galardi S,Mangiola A,et al.Extensive modulation of a set of microRNAs in primary glioblastoma[J].Biochem.Biophys.Res.Commun,2005,334:1351-1358.
41.Chan JA,Krichevsky AM,Kosik KS.MicroRNA-21 is an antiapoptotic factor in human glioblastoma cell[J]s.Cancer Res,2005,65:6029-6033.
42.He HL,Jazdzewski K,Li W,et al.The role of microRNA genes in papillary thyroid carcinoma[J].Proc.Natl.Acad.Sci.U.S.A,2005,102:19075-19080.
43.Kolfschoten IGM,van Leeuwen B,Berns K,et al.A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity[J].Cell,2005,121:849-858.
44.Voorhoeve PM,Agami R.The tumor-suppressive functions of the human INK4A locus[J].Cancer Cell,2003,4:311-319.
45.Mark Bloomston,Wendy L,Frankel,et al.MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis [J].JAMA,2007,297:1901-1908.
2.Jong-wook L.Global health improvement and WHO shaping the future.Lancet.2003,362:2083-2088.
3.Sherman M.Hepatocellular carcinoma:epidemiology,risk factors,and screening.Semin Liver Dis.2005,25:143-154.
4.Bosch FX,Ribes J,Diaz M,et al.Primary liver cancer:worldwide incidence and trends.Gastroenterology.2004,127:S5-S1.
5.Clark EA,Golob TR,Lander ES,et al.Genomic analysis of metastasis reveals an essential role for Rhoc[J],Nature.2000,406:532-535.
6.Machesky LM,Hall A.Rho:a connection between membrane recep2 for signalling and the cytoskeleton.Trends Cell B iol,1996,6(8):3042 310.
7.Oxford G,Theodorescu D.Ras superfamily monomeric G proteins in carcinoma cell motility.Cancer Letters,2003,189(2):117-128.
8.Celina GK,Kent AG,Michael SS,et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.Breast Cancer Research and Treatment.2005,93:101-110.
9.Kondo T,Sentani K,Oue N,et al.Exp ressi on of RhoC is ass ociated with metastasis of gastric carcinoma.Pathobiology.2004,71(1):19-25.
10.TakamuraM,SakamotoM,Genda T,et al.I nhibiti on of intrahepatic metastasis of human hepatocellular carcinoma by Rho2 associated protein kinase inhibitor Y2 27632.Hepatology.2001,33 (3):2.
11.Tomari Y,Zamore PD.MicroRNA biogenesiss:drosha can't cut it without a partner.Curr Biol.2005,15(2):R61-64.
12.Lewis BP,Burge CB,Bartel DP.Conserved seed pairing,often flanked by adenosines,indicates that thousands of human genes are microRNA targets.Cell.2005.120:15-20.
13.Zhang BH,Wang QL,Pan XP.MicroRNAs and their regulatory roles in animals and plants.J Cell Physiol.2007,210:279-289.
14.Calin G.A,Sevignani C,Dan Dumitru C,et al.Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.Proc.Natl.Acad.Sci.U.S.A.2004,101:2999-3004.
15.Voorhoeve PM,le Sage C,Schrier M,et al.Agenetic serene implicates miRNA-372 and miRNA-373 as oncogenes in testicular germcell tumors.Cell.2006,124(6):1169-1181.
16.Johnson SM,Grosshans H,Shingara J,et al.RAS is regulated by the let-7 microRNA family.Cell.2005,120(5):635-647.
17.Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.Cancer Res.2004,64(11):3753-3756.
18.Calin GA,Dumitru CD,Shimizu M,et al.Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc Natl Acad Sci USA.2002,99:15524-15529
19.Michael MZ,AM OC,Van Hoist Pellekaan NG,et al.Reduced accumulation of specific microRNAs in colorectal neoplasia.Mol Cancer Res.2003,1(12):882-891.
20.Ciafre SA,Galardi S,Mangiola A,et al.Extensive modulation of a set of microRNAs in primary glioblastoma.Biochem Biophys Rse Commun.2005,334(4):1351-1358.
21.Iorio MV,Ferracin M,Liu CG,et al.MicroRNA gene expression deregulation in human breast cancer.Cancer Res.2005,65(16):7065-7070.
22.Yanaihara N,Caplen N,Bowan E,et al.Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.Cancer Cell.2006,9(3):189-198.
23.Ma L,Teruya-Feldstein J,Weinberg RA.Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature.2007,449:682-688.
1.World Health Organization.Mortality database.Available from:URL:http://www.who.int/whosis/en
2.Jong-wook L.Global health improvement and WHO shaping the future.Lancet.2003,362:2083-2088.
3.Sherman M.Hepatocellular carcinoma:epidemiology,risk factors,and screening.Semin □ Liver □ Dis.2005,25:143-154.
4.Bruix J,Llovet,J.M.Prognostic prediction and treatment strategy in hepatocellular carcinoma.Hepatology.2003,35:519-524.
5.Tang ZY,Yu YQ,Zhou XD,et al.Progress and prospects in hepatocellular carcinoma surgery.Ann Chir.1998,52:558-563.
6.陈杰.肝脏、胆道及胰腺疾病.见:陈杰,李甘地,主编.病理学,第一版,北京:人民卫生出版社,2005,294.
7.Zachary D.G,LuigiM.T,Tumours and tumour-like lesions of the liver.In: Alastair D.B,Bernard C.P,Linda D.F.eds.Macsween's pathology of the liver.5 ed.Philadephia:Elsevier.2007,777-785.
8.S.Hirohas,K.G.Ishak,M.Kojiro,et al.Hepatocellular carcinoma.In:Stanley R.Hamilton,Lauri A.Aaltonen.Eds.Pathology and Genetics of Tumours of the Digestive System.Lyon:IARCPress.2003,164-166.
9.Ishak KG,Goodman ZD,Stocker JT.Tumors of the liver an intrahepatic bile ducts.Atlas of tumor pathology,3~(rd) Series,Fascicle 31.Washington:Armed Forces Institute of Pathology.2001.
10.Scheuer PJ.Classification of chronic viral hepatitis.A need for reassessment.J Hepatol.1991,13:372-374.
11.Bosch FX,Ribes J,Diaz M,et al.Primary liver cancer:Worldwide incidence and trends.Gastroenterology.2004,127:S5-S16.
12.Nagasue N,Ito A,Yukaya H,et al.Androgen receptors in hepatocellular carcinoma and surrounding parenchyma.Gastroenterology.1985,89:643-647.
13.Montalto G,Cervello M,Giannitrapani L,et al.Epidemiology,risk factors,and natural history of hepatocellular carcinoma.Ann N Y Acad Sci.2002,963:13-20.
14.Michielsen PP,Francque SM,van Dongen JL.Viral hepatitis and hepatocellular carcinoma.World J Surg Oncol.2005,3:27.
15.Edmondson HA,Steiner PE.Primary carcinoma of the liver:A study of 100 cases among 48900 necropsies.Cancer.1954,7:462-503.
16.Lauwers GY,Terris B,Balis UJ,et al.Prognostic histologic indicators of curatively resected hepatocellular carcinoma:a multi-institutional analysis of 425 patients with definition of a histologic prognostic index.Am J Surg Pathol.2002,26:25-34.
17.Nzeako UC,Goodman ZD,Ishak KG.Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma.Cancer.1995,76:579-588.
18.Llovet JM,Bustamante J,Castells A,et al.Natural history of untreated nonsurgical hepatocellular carcinoma:rationale for the design and evaluation of therapeutic trials.Hepatology.1999,29(1):62-67.
19.El-Assal ON,Yamanoi A,Soda Y,et al.Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma.Surgery.1997,122:571-577.
20.Villa E,Moles A,Ferretti I,et al.Natural history of inoperable hepatocellular carcinoma:estrogen receptors' status in the tumor is the strongest prognostic factor for survival.Hepatology.2000,32:233-238.
1.Sahai E,Marshall CJ.RhoGTPases and cancer.Nat Rev Cancer.2002,2:133-142.
2.Celina GK,Kent AG,Michael SS,et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.Breast Cancer Research and Treatment.2005,93:101-110.
3.Na L,Guoyun Zh,Feng B,et al.RhoC is essential for the metastasis of gastric cancer.J Mol Med.2007,85:1149-1156.
4.Wei W,Lian-Yue Y,Zhi-Li Y,et al.Expression and significance of RhoC gene in hepatocellular carcinoma.World J Gastroenterol.2003,9(9):1950-1953.
5.Joo M,Kang YK,Kim MR,et al.CyclinD 1 overexpression in hepatocellular carcinoma.Liver.2001,21:89-95.
6.Gartd AL,Radhakfishnan SK.Lost in transeription:p 21 repression mechanisms,and consequences.Cancer Res.2005,65(10):3980-3985.
7.Katiyar S,Dash BC,Thakur V,et al.P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.Cancer.2000,88:1565-1573.
8.KL Watts,E Cottrell,PR Hoban,et al.RhoA signaling modulates cyclin D1expression in human lung fibroblasts;implications for idiopathic pulmonary fibrosis.Respiratory Research.2006,7:88.
9.Welsh CF:Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation.Breast Cancer Res Treat.2004,84(1):33-42.
10.Filmus J,Selleck SB.Glypicans:proteoglycans with a surprise.J Clin Invest.2001,108:497- 501.
11.Sung YK,Hwang SY,Park MK,et al.Glypican-3 is overexpressed in human hepatocellular carcinoma.Cancer Sci.2003,94:259-262.
12.Nakatsura T,Kageshita T,Ito S,et al.Identification of glypican-3 as a novel tumor marker for melanoma.Clin Cancer Res.2004,10:6612-6621.
13.Zynger DL,Dimov ND,Luan C,et al.Glypican 3:a novel marker in testicular germ cell tumors.Am J Surg Pathol.2006,30:1570-1575.
14.Clark EA,Golub TR,Lander ES,et al.Genomic analysis of metastasis reveals an essential role for RhoC [J].Nature.2000,406 (6795):532-535.
15.Kondo T,Sentani K,Oue N,et al.Exp ressi on of RhoC is ass ociated with metastasis of gastric carcinoma.Pathobiology.2004,71 (1):19-25.
16.Bohmer RM,Scharf E,Assoian RK.Cytoskeletal integrity is required throughout the mitogen stimulation phase of the cell cycle and mediates the anchorage-dependent expression of cyclinD1.Mol.Biol.Cell.1996,7:101-111.
17.Nobes CD,Hall A.Rho,Rac,and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers,lamellipodia,and filipodia.Cell.1995,81,53-62.
18.Catherine F,Welsh,Kristin R,et al.Timing of cyclindl espression within G1 phase is controlled by RHO.Natrre cell biology.2001,3:950-957.
19.Quelle DE,Ashmun RA,Shurtleff SA,et al.Overexpression of mouse D-type cyclins accelerates Gl phase in rodent fibroblasts.Genes Dev.1993,7:1559-1571.
20.Bodrug SE,Warner BJ,Bath ML,et al.Cyclin Dl transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene.EMBO J.1994,13:2124-2130.
21.Gladden AB,Woolery R,Aggarwal P,et al.Expression of constitutively nuclear cyclin Dl in murine lymphocytes induces B-cell lymphoma.Oncogene.2006,25:998-1007.
22.Azechi H,Nishida N,Fukuda Y,et al.Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas.Oncology.2001,60:346-354.
23.Choi YL,Park SH,Jang JJ,et al.Expression of the G1-S modulators in hepatitis B virus-related hepatocel lular carcinoma and dysplastic nodule:association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma J Korean Med Sci.2001,16:424-432.
24.Somasundaram K,Zhang H,Zeng YX,et al.Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.Nature.1997,389:187-190.
25.Caffo O,Doglioni C,Veronese S,et al.Prognostic value of p21(WAF1) and p53 expression in breast carcinoma:an immunohistochemical study in 261patients with long-term follow-up.Clin Cancer Res.1996,2:1591-1599.
26.Thor AD,Liu S,Moore DH,et al.p(21WAF1/CIP1) expression in breast cancers:associations with p53 and outcome.Breast Cancer Res Treat.2000,61:33-43.
27.Nemes JA,Nemes Z,Mrton IJ.p21WAF1/CIP1 expression is a marker of poor prognosis in oral squamous cell carcinoma.J Oral Pathol Med.2005,34(5):274-279.
28.Mitomi H,Ohkura Y,Fukui N.P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis.Eur J Gastroenterol Hepatol.2007.19(10):883-889.
29.Domagala W,Welcker M,Chosia M,et al.p21/WAF1/Cip1 expression in invasive ductal breast carcinoma:relationship to p53,proliferation rate,and survival at 5 years.Virchows Arch.2001,439:132-140.
30.Primdahl H,von der Maase H,Sorensen FB,et al.Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer.J Cancer Res Clin Oncol 2002;128:295-301.
31.Gohring UJ,Bersch A,Becker M,et al.p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.J Clin Pathol.2001,54:866-870.
32.Lipponen P,Aaltomaa S,Eskelinen M,et al.Expression of p21(Wafl/Cip1) protein in transitional cell bladder tumours and its prognostic value.Eur Urol.1998,34:237-243.
33.Kao JT,Chuah SK,Huang CC.P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.Liver Int.2007,27(6):772-781.
34.Park YN,Chae KJ.Kwon KW.p53 and p21WAF1/CIP1 in hepatitis B virus related hepatocarcinogenesis.Hepatogastroenterologv.2003,50(53):1292-1296.
35.McClelland RA,Gee JM,O'Sullivan L,et al.p21(WAF1) expression and endocrine response in breast cancer.J Pathol.1999,188:126-130.
36.Susumu Kobayashi,Kazuyuki Matsushita,Kenichi Saigo,et al.p21WAF1/CIP1 Messenger RNA Expression in Hepatitis B,C Virus-Infected Human Hepatocellular Carcinoma Tissues.CANCER.2001,91 (11):2096-2103.
37.Qin LF,Ng IP.Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma:clinicopathologic correlation and survival analysis.Hum Pathol.2001,32(8):778-784.
38.Park YN,Chae KL Kwon KW,et al.p53 and p21WAF1/CIP1 in hepatitis B virus related hepatocarcinogenesis.Hepatogastroenterology.2003,50(53):1292-1296.
39.Bouchard MJ,Wang L,Schneider RJ.Activation of focal adhesion kirtase by hepatitis B virus HBx protein:multiple functions in viral replication.J Virol.2006,80:4406-4414.
40.Fujimoto Y,Hampton LL,Wirth PJ,et al.Alterations of Tumor Suppressor Genes and Allelic Losses in Human Heoatocellular Carcinomas in China.Cancer Res.1994,54(1):281-285.
41.White GR,Kelsey AM,Varley JM,et al.Somatic glypican-3(GPC3) mutations in Wilm' tumour.Br J Cancer.2003,86:1920-1922.
42.Capurro M,Wanless IR,Sherman M,et al.Gylpican-3:a novel serum and histochemical marker for hepatocellular carcinoma.Gastroenterology.2003,125:89-97.
43.Yamauchi N,Watanabe A.Hishinuma M,et al.The glypican-3 oncofetal protein is a promising siagnostic marker for hepatocellular carcinoma.Mod Pathol.2005,18:1591-1598.
44.Zhu ZW,Friess H,Wang L,et al.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.Gut.2001,48:558-564
45.Coggin,J.H.Jr.The implications of embryonic gene expression in neoplasia.CRC Crit.Rev.Onco J Hemat.1992,5:37-55.
46.M J Pellikainen,T T Pekola,K M Ropponen,et al.p21WAF1 expression in invasive breast cancer and it association with p53,AP-2,cell proliferation,and prognosis.J Clin Pathol.2003,56:214-220.
1.Tung P,Poon R,Fan ST,et al.Risk factors,prevention,and management of postoperative recurrence after resection of hepatocellular carcinoma.Ann Surg.2000,232:10-24.
2.Clark EA,Golub TR,Lander ES,et al.Genomic analysis of metastasis reveals an essential role for RhoC.Nature.2000,406 (6795):5322 535.
3.Celina GK,Kent AG,Michael SS,et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.Breast Cancer Research and Treatment.2005,93:101-110.
4.Na L,Guoyun Z,Feng B,et al.RhoC is essential for the metastasis of gastric cancer,J Mol Med.2007,85:1149-1156.
5.Wei W,Lian-Yue Y,Zhi-Li Y,et al.Expression and significance of RhoC gene in hepatocellular carcinoma,World J Gastroenterol.2003,9(9):1950-1953
6.Lewis BP,Burge CB,Bartel DP.Conserved seed pairing,often flanked by adenosines,indicates that thousands of human genes are microRNA targets.Cell.2005,120:15-20.
7.Xie XH,Lu J,Kulbokas EJ,et al.Systematic discovery of regulatory motifs in human promoters and 3'UTRs by comparison of several mammals.Nature.2005,434:338-345.
8.Calin GA,Croce C M.MicroRNA signatures in human cancers.Nature Rev.Cancer.2006,6:857-866.
9.Ma L,Teruya-Feldstein J,Weinberg RA.Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature.2007,449:682-688.
10.Fu HJ,Zhu J,Yang M,et al.A novel method to monitor the expression of microRNAs.Mol Biotechnol.2006,32:197-204.
11.Lee RC,Feinbaum RL,Ambros V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.Cell.1993,75:843-854.
12.Reinhart BJ,Slack FJ,Basson M,et al.The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans.Nature.2000,403:901-906.
13.Pasquinelli AE,Reinhart BJ,Slack F,et al.Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA.Nature.2000,408:86-89.
14.Denli AM,Tops BBJ,Plasterk RHA,Ketting RF,Harmon et al.Processing of primary microRNAs by the microprocessor complex.Nature.2004,432:231.
15.Forstemann K,Tomari Y,Du TT,et al.Normal microRNA maturation and germ-line stem cell maintenance requires loqua-cious,a double-stranded RNA-binding domain protein.Plos Biol.2005,3:1187-201.
16.Zhang BH,Pan XP,Cobb GP,et al.microRNAs as oncogenes and tumor suppressors.Dev Biol.2007,302:1-12.
17.Zhang BH,Wang QL,Pan XP.MicroRNAs and their regulatory roles in animals and plants.J Cell Physiol.2007,210:279-289.
18.Bentwich I,Aviniel A,Karov Y,et al.Identification of hundreds of conserved and nonconserved human microRNAs.Nature Genet.2005,37(7):766-770.
19.Xie XH,Lu J,Kulbokas EJ,et al.Systematic discovery of regulatory motifs in human promotersand 3'UTRs by comparison of several mammals.Nature.2005,434:338-345.
20.Zhang BH,Pan XP,Anderson TA.MicroRNA:a new player in stem cells.J Cell Physiol.2006,209:266-269.
21.Volinia S,Calin GA,Liu CG,et al.A microRNA expression signature of human solid tumors defines cancer gene targets.Proc.Natl.Acad.Sci.U.S.A.2006,103:2257-2261.
22.Calin GA,Dumitru CD,Shimizu M,et al.Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc Natl Acad Sci USA.2002,99:15524-15529.
23.Esquela-Kerscher A,Slack FJ.Oncomirs-microRNAs with a role in cancer.Nature Rev.Cancer.2006,6:259-269.
24.Johnson SM.et al.RAS is regulated by the let-7 microRNA family.Cell.2005,120:635-647.
25.Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.Cancer Res.2004,64(11):3753-3756.
26.Iorio MV,Ferracin M,Liu CG,et al.MicroRNA gene expression deregulation in human breast cancer.Cancer Res.2005,65(16):7065-7070.
27.Volinia S,Calin GA,Lin CG,et al.A microRNA expression signature of human solid tumors define cancer gene targets.Proc Natl Acad Sci USA.2006,103(7):2257-2261.
28.He L,Thomson JM,Hemann MT,et al.A microRNA polycistron as a potential human oncogene.Nature.2005,435(7043):828-833.
29.Garzon R,Garofalo M,Martelli MP,et al.Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.PNAS.2008,105:3945-3950.
30.Falini B,Nicoletti I,Martelli FM,et al.Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc_ AML):Biological and clinical features.Blood.2007,109:874-885.
31.Ladeiro Y,Couchy G,Balabaud C,et al.MicroRNA Profiling in Hepatocellular Tumors Is Associated with Clinical Features and Oncogene/Tumor Suppressor Gene Mutations.Hepatology.2008,47:1955-1963.
32.Oxford G,Theodorescu D.Ras superfamily monomeric G p roteins in carcinoma cell motility.Cancer Letters.2003,189 (2):117-128.
1.Motola-Kuba D,Zamora-Valdes D,Uribe M,et al.Hepatocellular carcinoma.An overview.Ann Hepatol,2006,5:16-24.
2.Gorog D,Regoly-Merei J,Paku S,et al.Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.World-J-Gastroenterol,2005,11(32):5015-5018.
3.Ramos Vara JA,Miller MA,Johnson GC.Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.Vet-Pathol,2001,38(6):636-643.
4.Lugli A,Tornillo L,Mirlacher M,et al.Hepatocyte paraffin 1 expression in human normal and neoplastic tissues:tissue microarray analysis on 3,940 tissue samples[J].Am-J-Clin-Pathol,2004,122(5):721-727.
5.Zhu ZW,Friess H,Wang L,et al.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders[J].Gut.,2001,48(4):558-564.
6.Yamauchi N,Watanabe A,Hishinuma M,et al.The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma[J].Mod-Pathol,2005,18(12):1591-1598.
7.Wang XY,Degos F,Dubois S,et al.Glypican-3 expression in hepatocellular tumors:diagnostic value for preneoplastic lesions and hepatocellular carcinomas[J].Hum-Pathol,2006,37(11):1435-1441.
8.Libbrecht L,Severi T,Cassiman D,et al.Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis,dysplastic nodules,and focal nodular hyperplasia-like nodules[J].Am-J-Surg-Pathol,2006,30(11):1405-1411.
9.De Boer WB,Segal A,Frost FA,et al.Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies [J].Cancer,2000,90(5):273-278.
10.韩圣华,黄建富.新生血管生成与肝细胞癌侵袭、转移和预后的关系[J].中华肝胆外科杂志,2001,7(1):27-30.
11.Borscheri N,Roessner A,Rocken C.Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas[J].Am-J-Surg-Pathol,2001,25(10):1297-1303.
12.Xiao SY,Wang HL,Hart J,et al.cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma[J].Am-J-Pathol,2001,159(4):1415-1421.
13.Zimmerman RL,Logani S,Baloch Z.Evaluation of the CD34 and CD10immunostains using a two-color staining protocol in liver fine-needle aspiration biopsies[J].Diagn-Cytopathol,2005,32(2):88-91.
14.Stroescu C,Herlea V,Dragnea A,et al.The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas[J].J-Gastrointestin-Liver-Dis,2006,15(1):9-14.
15.Park YN,Kojiro M,Di-Tommaso L,et al.Ductular reaction is helpful in defining early stromal invasion,small hepatocellular carcinomas,and dysplastic nodules[J].Cancer,2007,109(5):915-923.
16.Athanassiadou P,Psyhoyiou H,Grapsa D,et al.Cytokeratin 8 and 18expression in imprint smears of chronic viral hepatitis,autoimmune hepatitis and hepatocellular carcinoma[J].A preliminary study.Acta-Cytol,2007,51(1):61-65.
17.Lemmer ER,de la Motte Hall P,Omori N,et al.Histopathology and gene expression changes in rat liver during feeding of fumonisin B_1,a carcinogenic mycotoxin produced by Fusarium moniliforme[J].Carcinogenesis,1999,20(5):817-824.
18.Chan KL,Guan XY,Ng IO.High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma[J].Hum-Pathol,2004,35(11):1324-1331.
19.朱斌,姚晓平,杨甲梅,等.原发性肝细胞癌中细胞周期G1期相关基因Cyclin D1的表达及其临床病理学意义[J].肝胆外科杂志,1999,7(3):214-216.
20.Wong CM,Fan ST,Ng IO.beta-Catenin mutation and overexpression in hepatocellular carcinoma:clinicopathologic and prognostic significance[J].Cancer,2001,92:136-145.
21.Zeng G,Apte U,Cieply B,et al.siRNA-Mediated beta-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival[J].Neoplasia,2007,9(11):951-959.
22.Suzuki K,Hayashi N,Yamada Y,et al.Expression of the c-met protooncogene in human hepatocellular carcinoma[J].Hepatology,1994,20(5):1231-1236.
23.Salvi A,Arici B,Portolani N,et al.In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells[J].Int J Oncol,2007,31(2):451-460.
24.Wang XW,Forrester K,Yeh H,et al.Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding,transcriptional activity,and association with transcription factor ERCC3[J].Proc Natl Acad Sci,1994,91:2230-2234.
25.Oda T,Tsuda H,Sakamoto M,et al.Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression[J].Cancer Lett,1994,83:197-200.
26.Bouchard M J,Wang L,Schneider RJ.Activation of focal adhesion kirtase by hepatitis B virus HBx protein:multiple functions in viral replication[J].J Virol,2006,80:4406-4414.
27.Fujimoto Y,Hampton LL,Wirth PJ,et al.Alterations of Tumor Suppressor Genes and Allelic Losses in Human Heoatocellular Carcinomas in China[J].Cancer Res 1994;54(1):281- 285.
28.Moghaddam S J,Haghighi EN,Samiee S,et al.Immunohistochemical analysis of p53,cyclinD1,RB1,c-fos and N-ras gene expression in hepatocellular carcinoma in Iran.[J].World-J-Gastroenterol,2007,13(4):588-593.
29.Hu TH,Wang CC,Huang CC,et al.Down-regulation of tumor suppressor gene PTEN,overexpression of p53,plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection[J].Oncol Rep,2007,18(6):1417-1426.
30.许荣华,易继林.FHIT基因蛋白的表达与肝癌的临床关系[J].临床外科杂志,2004,12(7):412-414.
31.Kannangai R,Sahin F,Adegbola O,et al.FHIT mRNA and protein expression in hepatocellular carcinoma[J].Mod-Pathol,2004,17(6):653-659.
32.Endo K,Ueda T,Ueyama J,et al.Immunoreactive E-cadherin,alpha-catenin,beta-catenin,and gamma-catenin proteins in hepatocellular c arcinoma:relationships with tumor grade,clinicopathologic parameters,and pati ents'survival[J].Hum Pathol,2000,31:558-565.
33.殷茜,陈孝平.细胞黏附分子CD44v6在肝癌组织中的表达及意义[J].世界华人消化杂志,2005,13(11):1295-1298.
34.Musso O,Th(?)ret N,Campion JP,et al.In situ detection of matrix metalloproteinase-2(MMP2) and the metalloproteinase inhibitor TIMP2transcripts in human primary hepatocellular carcinoma and in liver metastasis[J].J Hepatol,1997,26(3):593-605.
35.Murakami Y,Yasuda T,Saigo K,et al.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J].Oncogene,2006,25:2537-2545.
36.Meng F,Henson R,Wehbe-Janek H,et al.MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer[J].Gastroenterology,2007,133(2):647-58.Epub 2007 May 21.
1.Calin GA,Sevignani C,Dan Dumitru C,et al..Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J].Proc.Natl.Acad.Sci.U.S.A.2004,101:2999-3004.
2.Zhang BH,Pan XP,Cox SB,et al.Evidence that miRNAs are different from other RNAs[J].Cell.Mol.Life Sci.2006,63:246-254.
3.Iin H,Gregory J H.MicroRNAs:small RNAs with a big role in gene regulation[J].Nature Rev Genet,2004,5:522.
4.Xu PZ,Guo M,Hay BA.MicroRNAs and the regulationof cell death[J].Trends Genet,2004,20:617.
5.Volinia S,Calin GA,Liu CG,et al.A microRNA expression signature of human solid tumors defines cancer gene targets[J].Proc.Natl.Acad.Sci.U.S.A, 2006,103:2257-2261.
6.Zhang BH,Pan XP,Cobb GP,et al.Plant microRNA:a small regulatory molecule with big impact.Dev[J].Biol,2006,289:3-16.
7.Griffiths-Jones S,Grocock RJ,van Dongen S,et al.miRBase:microRNA sequences,targets and gene nomenclature [J].Nucleic Acids Res,2006,34:D140-D144.
8.Lee Y,Kim M,Han J,et al.MicroRNA genes are transcribed by RNA polymerase Ⅱ [J].EMBO J,2004,23(20):4051-4060.
9.Lee Y,Ann C,Han J,et al.The nuclear RNaselll Drosha initiates microRNA processing[J].Nature,2003,425:415-419.
10.Denli AM,Tops BB,Plasterk RH,et al.Processing of primary microRNAs by the microprocessor complex[J].Nature,2004,432:231-235.
11.Zeng Y,Cullen BR.Structural requirements for pre-microRNA binding and nuclear export by Exportin 5[J].Nucleic Acids Research,2004,32(16):4776-4785.
12.Hutvagner G,Zamore PD.A microRNA in a multiple-turnover RNAi enzyme complex[J].Science,2002,297:2056-2060.
13.Chen F,Yin QW.MiRNAs regulate the gene expression.Chinese Science Bulletin[J],2005,50(13):1289-1299.
14.Hutvagner G,Simard MJ,Mello CC,et al.Sequencespecific inhibition of small RNA function[J].PLOS Biol.2004,2:465-475.
15.Krutzfeldt J,Rajewsky N,Braich R,et al.Silencing of microRNAs in vivo with 'antagomirs' [J].Nature,2005,438:685-689.
16.Lewis BP,Burge CB,Bartel DP.Conserved seed pairing,often flanked by adenosines,indicates that thousands of human genes are microRNA targets[J].Cell,2005,120:15-20.
17.Lee RC,Feinbaum RL,Ambros V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J].Cell,1993,75:843-854.
18.Hayashita Y,Osada H,Tatematsu Y,et al.A polycistronic microRNA cluster,miR-17-92,is overexpressed in human lung cancers and enhances cell proliferation[J].Cancer Res,2005,65:9628-9632.
19.Bandres E,Cubedo E,Agirre X,et al.Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues[J].Molecular Cancer,2006,5:29.
20.Thomson JM,Parker J,Perou CM,et al.A custom microarray platform for analysis of microRNA gene expression[J].Nature Methods,2004,1:47-53.
21.Liang RQ,Li W,Li Y,et al.An oligonucleotide microarray for microRNA expression analysis based on labeling RNAwith quantum dot and nanogold probe[J].Nucleic Acids Res,2005,33:e17.
22.Lu J,Getz G,Miska EA,et al.MicroRNA expression profiles classify human cancers[J].Nature,2005,435:834-838.
23.Lewis BP,Shih IH,Jones-Rhoades,et al.Prediction of mammalian microRNA targets[J].Cell,2003,115:787-798.
24.Hammond SM.MicroRNAs as oncogenes[J].Curr.Opin.Genet.Dev.2006,16:4-9.
25.Voorhoeve PM,le Sage C,Schrier M,et al.A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors[J].Cell,2006,124:1169-1181.
26.Reinhart BJ,Slack FJ,Basson M,et al.The 21-nucleotide lct-7 RNA regulates developmental timing in Caenorhabditis elegans[J].Nature,2000,403(6672):901-906.
27.Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival[J].Cancer Res,2004,64:3753-3756.
28.Johnson SM,Grosshans H,Shingara J,et al.RAS is regulated by the let-7 microRNA family[J].Cell,2005,120:635-647.
29.Calin GA,Dumitru CD,Shimizu M,et al.Frequent de2 letions and down2regulation of micro2RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia[J].Proc Natl Acad Sci U S A,2002,99 (24):15524-15529.
30.Calin GA,Liu CG,Sevignani C,et al.MicroRNA profiling reveals distinct signatures in B cell chroniclymphocytic leukemias[J].Proc.Natl.Acad.Sci.U.S.A,2004,101:11755-11760.
31.Cimmino A,Calin GA,Fabbri M,et al.miR-15 and miR-16 induce apoptosis by targeting BCL2[J].Proc.Natl.Acad.Sci.U.S.A.,2005,102;13944-13949.
31.He L,Thomson JM,Hemann MT,et al.A microRNA palycistron as a potential human oncogene[J].Nature,2005,435:828-833.
32.Tam,W.Identification and characterization of human BIC,a gene on chromosome 21 that encodes a noncoding RNA[J].Gene,2001,274:157-167.
33.Eis PS,Tam W,Sun LP,et al.Accumulation of miR-155 and BIC RNA in human Bcell lymphomas[J].Proc.Natl.Acad.Sci.U.S.A,2005,102:3627-3632.
34.Murakami Y,Yasuda T,Saigo K,et al.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J].Oncogene,2006,25:2537-2545.
35.Yingqiu Guo,Yongxin Chen,Hirotaka Ito,et al.Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma[J].Gene,2006,384:51-61.
36.Yang J,Zhou F,Xu T,et al.Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas [J].Mutat Res,2008,628(1-2):205-209.Epub 2007 Aug 21.
37.Meng F,Henson R,Wehbe-Janek H,et al.MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer[J].Gastroenterology,2007,133(2):647-58.Epub 2007 May 21.
38.Iorio MV,Ferracin M,Liu CG,et al.MicroRNA gene expression deregulation in human breast cancer[J].Cancer Res,2005,65:7065-7070.
39.Michael MZ,O'Connor SM.,Pellekaan NGV,et al.Reduced accumulation of specific microRNAs in colorectal neoplasia[J].Mol.Cancer Res,2003,1:882-891.
40.Ciafre SA,Galardi S,Mangiola A,et al.Extensive modulation of a set of microRNAs in primary glioblastoma[J].Biochem.Biophys.Res.Commun,2005,334:1351-1358.
41.Chan JA,Krichevsky AM,Kosik KS.MicroRNA-21 is an antiapoptotic factor in human glioblastoma cell[J]s.Cancer Res,2005,65:6029-6033.
42.He HL,Jazdzewski K,Li W,et al.The role of microRNA genes in papillary thyroid carcinoma[J].Proc.Natl.Acad.Sci.U.S.A,2005,102:19075-19080.
43.Kolfschoten IGM,van Leeuwen B,Berns K,et al.A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity[J].Cell,2005,121:849-858.
44.Voorhoeve PM,Agami R.The tumor-suppressive functions of the human INK4A locus[J].Cancer Cell,2003,4:311-319.
45.Mark Bloomston,Wendy L,Frankel,et al.MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis [J].JAMA,2007,297:1901-1908.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |